.png)
.png)
Head of Infectious Diseases Therapy Area
Brii Biosciences
Disclosure(s): Brii Biosciences: Stocks/Bonds
David Margolis is an ID trained physician with a masters in public health, who currently serves as the Head of the Infectious Diseases Therapy area for Brii Biosciences. He recieved his medical training from Duke University and his Infectious Diseases fellowship from the University of California, San Diego, where he researched the innate immune response to Aspergillus fumigatus, and focused on the clinical managment of immunosuprressed patients. Following his academic career, Daivd worked for 11 years at GSK and ViiV, leading the devlopment of several HIV drug programs, including the long acting cabotegravir program, which lead to the first ever approval of a long acting treatment regimen for HIV, Cabenuva, and of two positive Phase 3 studies evaluating cabotegravir for the prevention of HIV. His current role includes oversight of a number of development programs, across HIV, MDR bacteria therapies and COVID monoclonal antibodies, BRII-196 and BRII-198. In his free time he is raising three future researchers.